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ABSTRACT 
 
Twelve previously synthesized biologically active 2,6,7-trihydroxy-9-aryl-3H-xanthen-3-one derivatives 
(1-12) were evaluated in vitro for their antimicrobial activity against four bacteria, S. aureus, B. subtilis P. 
aeruginosa and E. coli, and two fungi strains, C. albicans and S. cerevisiae. The most potent compound were 
derivatives 1 which possess hydroxyl group and bromine as substituent and 11 with bromine as substituent on 
phenyl ring. The results indicate that bromine increase antimicrobial activity of 2,6,7-trihydroxy-9-aryl-3H-
xanthen-3-one derivatives. Compound 7 with ethoxy substituent on phenyl ring showed the least activity 
against tested bacteria and fungi strains, which is in line with an earlier observation that ethoxy substitution 
decreases antimicrobial activity. The most and the least potent compounds were subjected to molecular 
docking simulations to preliminary find out the potential molecular target and at the same moment further 
support the experimental antimicrobial test of xanthen derivatives. 
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INTRODUCTION 
 
Xanthen derivatives are compounds with important biological activities such as immunomodulating [1], 
antitumor [2], antimalarial [3], antioxidant [4], antimalarial [5], antifungal [6] and antibacterial activity [7]. 
Xanthens have also been reported for thair antileukemic [8], antiinflammatory [9] and apoptic effects [10]. 
Due to their wide range of applications, xanthene derivatives have received a great deal of attention regarding 
their synthesis and research as potential pharmacological active agents. In recent years, because of their 
antimicrobial activity, these compounds are in focus of research. Also, researches try to explain mechanism of 
their antimicrobial activity. Related to the problem of microbial resistance, a number of enzymes and 
receptors important for microbial growth may be considered as potential targets for new drugs.  
 
Cytochrome P450 isoenzyme 51 is a family of phylogenetic highly conserved monooxygenases found in 
mycobacteria, fungi, plants, animals and humans. The ideal antifungal agent should be a potent inhibitor of 
fungal CYP51 while leaving the human CYP51 unaffected [11, 12]. 
 
As such validated targets are recognized as major pillars in the drug discovery and drug development 
process, a number of in silico methods are used to identify potential targets and interactions of small 
molecules with target proteins in the cell. Among them, molecular docking is a popular method to study 
binding of small molecules (ligands) to macromolecules (receptor). In particular, the efficiency of Autodock 
program has been well demonstrated for that purpose in several studies [13, 14, 15].  
 
In our previous work [16, 17] we synthesized 9-aryl substituted 2,6,7-trihydroxyxanthen-3-one 
derivatives using reliable one-pot synthesis followed by structure elucidating measurements, and performed 
antioxidant and antiplatelated potency evaluation. Antimicrobial and antiproliferative studies on similar 
xanthenes were reported [18, 19, 20]. Presented study therefore, was aimed to evaluate antimicrobial effects 
of synthesized 9-aryl substituted xanthen-3-ones. The most potent compound was subjected to molecular 
docking simulations.  
 
EXPERIMENTAL 
 
In our previos work we synthesized and confirmed structure of twelve xanthen-3-one derivatives 
(1−12), Figure 1, from 1,2,4-triacetoxybenzene and different aromatic aldehydes under acidic alcoholic 
conditions. After a two-fold Friedel-Crafts alkylation intermediate A was obtained. For accomplishing the 
transformation, a single trihydroxy benzene moiety of A had to be oxidized using potassium peroxodisulphate 
to the corresponding p-benzoquinone. To avoid decomposition of potassium peroxodisulphate, the reaction of 
oxidation occurred at 80°C. Benzoquinone intermediate (B) subsequently underwent a cyclocondensation 
reaction to the xanthenone fragment. To remove potassium peroxodisulphate after completed oxidation, 
refluxed suspension was poured onto ice water and filtered. The residue was dried under vacuum at 60 °C [16, 
21]. 
 
Antimicrobial activity 
 
Antibacterial activity was tested by the diffusion method against Bacillus subtilis ATCC 6051, 
Staphylococcus aureus ATCC 6538P, Escherichia coli ATCC 9027 and Pseudomonas aeruginosa ATCC 9027, 
while antifungal activity was tested against Candida albicans ATCC 1023 and Saccharomyces cerevisiae ATCC 
9763. Test samples were dissolved in 99.5% dimethyl sulfoxide (DMSO) to obtain a 1 mg/mL stock solutions 
which were then applied to Müller-Hinton and Sabouraud nutritious bases. The inhibition zones for bacteria 
were measured in millimetres at the end of an incubation period of 18 h at 37 °C, and for fungal strains after 
48 h at 25 °C. Compounds were further tested by dilution method. For this, Casein soya bean digest broth 
(Triptic soya bujon) was used. As referent compounds chloramphenicol and fluconazole were used in 
concentration of 500 µg/mL. Test solution of the compound was prepared, followed by formation of a series of 
12 dilutions with liquid nutritious base. After the incubation for 24 h, the last tube with no growth of 
microorganisms was taken to represent minimum inhibitory concentration (MIC) expressed in mg/mL. The 
concentrations of the prepared solutions were in range 0.5–0.00024 mg/mL. 
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Figure 1: Synthesis and structure of xanthen-3-on derivatives 
 
Docking study and physicochemical properties calculations 
 
Lamarckian Genetic Algorithm of the AutoDock 4.0 program was used to perform the flexible-ligand 
docking studies [22]. Receptors’ X-ray crystal structures obtained from the Brookhaven protein data bank were 
applied in docking studies (http://www.pdb.org/). 
 
Prior to actual docking run, AutoGrid 4.0 was introduced to precalculate grid maps of interaction 
energies of various atom types. In all dockings, a grid map with 126*126*126 points, a grid spacing of 1.000 Å. 
In an AutoGrid procedure, the protein is embedded in a 3D grid and a probe atom is placed at each grid point. 
The energy of interaction of this single atom with the protein is assigned to the grid point. Autodock 4.0 uses 
these interaction maps to generate ensemble of low energy conformations. It uses a scoring function based on 
AMBER force field, and estimates the free energy of binding of a ligand to its target. For all dockings, 10 
independent runs with step sizes of 0.2 Å for translations and 5 Å for orientations and torsions, an initial 
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population of random individuals with a population size of 150 individuals, a maximum number of 250000 
energy evaluations and 27000 maximum generations.  
 
Bindings between docked potent agents and related macromolecule were analysed using Autodock 
tools program (ADT, Version 1.5.4) and PyMol-1.1 software that was used for graphical visualization, analysing 
interactions of ligands and receptors and producing quality of images [23]. 
 
As receptors in docking simulations topoisomerase II (pdb: 1BGW) and CYP51 (pdb: 2WX2) were used. 
 
RESULTS AND DISSCUSION 
 
Results of antimicrobial activity 
 
Synthesized xanthene derivatives were tested for microbiological activity by diffusion and 
microdilution method on four strains of bacteria and two strains of fungi. The tests were performed on two 
gram negative bacteries Escherichia coli ATCC 9027 and Pseudomonas aeruginosa ATCC 15442 and two gram 
positive bacteries, Staphylococcus aureus ATCC 6538P and Bacillus subtilis ATCC 6051. The antifungal activity of 
synthetized xanthene compounds was tested on fungi Candida albicans ATCC 1023 and Saccharomyces 
cerevisiae ATCC 9763. As standard in the study, chloramphenicol (for antibacterial testing) and fluconazole (for 
the examination of antifungal activity) were used. The results of antimicrobial activity are shown in Tables 1 
and 2. 
 
Table 1: Results of antimicrobial activity 
 
Compound 
Minimum Inhibitory Concentration mg/ml 
(Millimeters of zone inhibition) 
Escherichia  coli 
(ATCC 9027) 
Pseudomonas 
aeruginosa 
(ATCC 15442) 
Staphylococcus 
aureus 
(ATCC 6538P) 
Bacillus subtilis 
(ATCC 6051) 
     
1 0.156 (20,5) 0.626 (18.0) 0.078 (22.5) 0.156 (21.5) 
2 0.313 (16.0) 1.250 (13.0) 0.626 (16.5) 0.626 (14.0) 
3 0.313 (16.0) 1.250 (14,5) 0.626 (15.0) 1.250 (11.5) 
4 0.626 (11.0) 1.250 (16.0) 0.626 (16.0) 2.500 (14.0) 
5 0.626 (10.0) 1.250 (12.0) 1.250 (18.5) 1.250 (12.0) 
6 0.626 (11.0) 1.250 (14.5) 0.626 (18.5) 1.250 (11.5) 
7 1.250 (8.0) 1.250 (16.0) 1.250 (14.0) 1.250 (11.5) 
8 0.626 (12.0) 1.250 (13.0) 1.250 (11.0) 0.626 (13.5) 
9 0.626 (10.0) 1.250 (13.5) 0.313 (14.5) 0.626 (11.0) 
10 0.626 (12.5) 1.250 (16.5) 0.626 (19.5) 1.250 (19.0) 
11 0.156 (18,5) 0.626 (18.5) 0.078 (20.0) 0.313 (20.0) 
12 0.626 (14.5) 1.250 (15.0) 1.250 (16.0) 0.626 (19.5) 
Chloramphenicol 0.078 (23.5) - 0.010 (24.0) 0.010 (22.5) 
 
Table 2: Results of antifungal activity 
 
 
Compound 
Minimum Inhibitory Concentration mg/ml 
(Millimeters of zone inhibition) 
Candida albicans 
(ATCC 1023) 
Sacharomyces cerevisiae 
(ATCC 9763) 
   
1 0.313 (18.5) 0.626 (20.0) 
2 - 0.626 (18.5) 
3 - 1.250 (16.0) 
4 - 1.250 (16.5) 
5 - 1.250 (16.0) 
6 - 0.626 (16.5) 
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7 - 1.250 (14.0) 
8 1.250 (17.5) 0.626 (16.5) 
9 - - 
10 - 0.626 (19.5) 
11 0.626 (18.0) 0.313 (20.0) 
12 - 0.626 (18.0) 
Fluconazole 0.313 (20.5) 0.313 (21.0) 
 
The in vitro antimicrobial activity of the compounds against gram positive Staphylococcus aureus and 
Bacillus subtilis bacteria strains and gram negative bacteria Escherichia coli and Pseudomonas aeruginosa was 
studied. Also, synthesized 2,6,7-trihydroxy-9-aryl-3H-xanthen-3-ones derivatives were tested for their 
antifungal activity against Candida albicans and Sacharomyces cerevisiae strains. The compounds were tested 
at a concentration of 1mg/mL using Triptic soya bujon. The diameter of growth inhibition zone were measured 
in millimeters of zone inhibition in diffusion method and in mg/mL in dilution method.  
 
The results indicate that all synthesized 2,6,7-trihydroxy-9-aryl-3H-xanthen-3-ones derivatives (1-12) 
showed significant antibacterial activity against tested bacterial strains. Also, only derivatives 1, 8 and 11 of 
tested compounds exhibited activity toward Candida albicans ATCC 1023. According to results the most potent 
antimicrobial agents were compounds 1 and 11. These compounds contain bromine substituent on phenyl 
ring, which correlates with literature described effect of bromine as substituent on antimicrobial activity [24].  
 
Described in vitro antibacterial activity of tetrahydrobenzoxanthene-11-one derivative against 
bacteria strains suggests that antibacterial activity increased with increasing number of hydroxy groups in 
molecule [25]. In our research the most potent antibacterial agents was compound 1 with bromine and 
hydroxy group substituted on phenyl ring. Thus, suggesting that the activity against these bacterial strains is 
dependent on the nature of substituent on phenyl ring and that bromine and hydroxy group in structure of 
2,6,7-trihydroxy-9-aryl-3H-xanthen-3-ones derivatives increase antimicrobial activity. The least potent was 
compound 7 with ethoxy substituent on phenyl ring. In literature are described that ethoxy substitution 
decrease antimicrobial activity of similar compound [26], which correlate with our results.  
 
Results of docking study 
 
Docking studies for the antibacterial activity of synthesized xanthene compounds were made for the 
most potent compound. As a receptor in docking simulations, topoisomerase II DNA gyrase was used, which is 
known to be the target site for the action of most antimicrobial agents, such as ciprofloxacin and 
chloramphenicol [27]. 
 
For compound 1, that was the most potent compound, docking studies have shown that this 
compounds bind to an enzyme topoisomerase II energy of -2.52 kcal/mol, thereby constructing three 
hydrogen bonds, one by oxygen from OH group in position C-2 and protons from the NH group of arginine 
(ARG 483), the other via the proton from the OH group at the C-2 position with oxygen glutamine 
topoisomerase II (GLU 484) and the third via the carbonyl group at the C-3 position with oxygen glutamine 
(GLU 484) enzyme topoisomerase II DNA gyrase (Figure 2). 
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Figure 2: Binding compound 1 on Topoisomerase II 
 
 
 
Figure 3: Binding compound 1 on CYP 51 
 
In order to explain why compound 1 shows better action than other synthesized xanthen-3-
derivatives, docking studies were also performed on the least potent xanthen-3-one derivative (compound 7). 
The results showed that compound 7 has the same binding sites on topoisomerase II as compound 1, but the 
binding energy is greater and was -2.05 kcal/mol. 
 
As a receptor in docking studies for antifungal activity, CYP 51 was used as a receptor,  which is the 
target site for the action of most antifungal agents, such as fluconazole and ketoconazole [12].  
 
The best antifungal activity among synthetized xanthen-3-one derivatives showed compound 1, which 
is bound to CYP 51 by a single hydrogen bond, via a carbonyl group in the C-3 of compound and NH group of 
the ARG 449 receptor group (Figure 3). 
 
The binding energy of compound 1 for CYP 51 was -5.85 kcal/mol, while for compound 9, which 
showed the lowest antifungal activity, was -0.61 kcal / mol. 
 
CONCLUSION 
 
Xanthen-3-one derivatives showed moderate antibacterial and antimycotic activities. Introduction of 
hydroxy group and bromide as substituents increased antimicrobial activity, while introduction of ethoxy 
ISSN: 0975-8585 
September–October 2018  RJPBCS 9(5)  Page No. 783 
group decreased it. Docking study revealed correlation between activity in vitro and binding energy in silico 
with topoisomerase II. Also, binding energies of synthesized compounds with receptor relevant for antifungal 
activity showed good correlation with antifungal activity in vitro. 
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